尼可地尔治疗心脏X综合征的效果
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2016年第1期
- 页码:
- 64-065,074
- 栏目:
- 临床研究
- 出版日期:
- 2015-09-15
文章信息/Info
- Title:
- Effect of nicorandil on cardiac syndrome X
- Author(s):
- Lü Yan; JIA Da-lin
- (Department of Cardiovascology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China)
- 分类号:
- R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 目的 观察尼可地尔治疗心脏X综合征(CSX)的效果。方法 选择2013年1月~12月在本科确诊的CSX的患者45例，随机分为试药组(n=23)及对照组(n=22)。两组患者均给予常规药物治疗，试药组在此基础上给予尼可地尔5 mg，每日3次口服，随访3个月，观察患者胸痛改善情况，复查平板运动试验。结果 对照组治疗后比治疗前劳累型心绞痛发作次数降低〔(29.8±5.5)次/月 vs.(20.4±4.5)次/月,P<0.05〕,试药组治疗后比治疗前降低〔(31.7±3.4)次/月 vs.(19.5±5.1)次/月，P<0.05〕。两组间比较试药组降低更加显著。两组的运动持续总时间、ST段最大压低幅度、运动试验中发作心绞痛人数均有改善，但试药组有更好的作用。结论 尼可地尔在心脏CSX患者治疗中能够在基本治疗基础上进一步改善心绞痛症状。
- Abstract:
- AIM To observe the clinical effect of nicorandil on patients with cardiac syndrome X and to analyze the treatment results. METHODSForty-five patients diagnosed with cardiac syndrome X between January 2013 and December 2013 in our hospital were enrolled and randomly divided into nicorandil group (n=23) and control group (n=22). Patients in the two groups were given routine drug treatment and, in addition, nicorandil 5 mg tid orally per day was given in nicorandil group. After a 3-month follow-up, chest pain was examined and treadmill exercise test was conducted. RESULTSAngina pectoris was reduced in both control group ［(29.8±5.5) Times/month vs.(20.4±4.5) Times/month, P<0.05］ and nicorandil group ［(31.7±3.4) Times/month vs.(19.5±5.1) Times/month, P<0.05］ with better results in nicorandil group. Total duration of exercise, maximal ST segment depression, and occurrence of angina in exercise test were improved in both groups, with better results in nicorandil group. CONCLUSION: Based on the basic treatment, nicorandil can further improve the symptoms of angina pectoris in patients with cardiac syndrome X.
参考文献/References
[1]Cannon RO，Epstein SE.“Microvascular angina”as a cause of chest pain with angiographically normal coronary arteries[J].Am J Cardiol,1988,61(15):1338-1343.
[2]Cocco G,Jerie P.Angina pectoris in patients without flow-limiting coronary artery disease(cardiac syndrome X).A forest of a variety of trees[J].Cardiol J,2015,doi:10.5603/CJ.a2015.0026.
[3]Kiyooka T,Kobayashi Y,Ikari Y.A case of vasospastic angina in which the ergonovine provocation test with intracoronary isosorbide dinitrate and nicorandil was effective in the diagnosis of microvascular spasm[J].Cardiovasc Interv Ther,2014,29(4):344-339.
[4]Hirohata A,Yamamoto K,Hirose E,et al.Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris:a randomised study[J].EuroIntervention,2014,9(9):1050-1056.
[5]黄 山，王大新.心脏X 综合征的诊治进展[J].心血管病防治知识,2015,(2):140-142.
[6]赵 洋，张金国.心脏X 综合征与血管内皮功能的相关性研究进展[J].医学综述,2013,19(1):133-135.
[7]李海英，朱彦凯.尼可地尔治疗心脏X综合征的临床疗效观察及安全性分析[J].中国医学创新,2013,10(27):127-128.
[8]Karpova IE,Samoǐlenko LE,Soboleva GN,et al.Adenosine triphosphate stress (99m)Tc-MIBI single-photon emission computed tomography in the diagnosis Miocardial Iscemia in patients with Microvascular Angina[J].Kardiologiia,2014,54(7):4-8.
备注/Memo
- 备注/Memo:
- 收稿日期：2015-06-12.
通讯作者：贾大林，教授，主要从事冠心病基础和临床研究 Email：JDL2001@263.net
作者简介：吕岩，讲师，博士 Email：lzyekai2009@163.com
常用功能
统计/Statistics
- 摘要浏览/Viewed704
- 评论/Comments
